Harmony Biosciences (HRMY) Files Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Harmony Biosciences (HRMY) Tops Q3 EPS by 22c
November 9, 2021 7:32 AM ESTHarmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $0.51, $0.22 better than the analyst estimate of $0.29. Revenue for the quarter came in at $80.7 million versus the consensus estimate of $80.92 million.
For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.
... More